Clinical Trials Logo

Cerebral Hemorrhage clinical trials

View clinical trials related to Cerebral Hemorrhage.

Filter by:

NCT ID: NCT01829581 Completed - OAC-ICH Clinical Trials

geRman-widE mulTicenter Analysis of oRal Anticoagulation-associated intraCerebral hEmorrhage

RETRACE
Start date: September 2011
Phase: N/A
Study type: Observational

Intracerebral hemorrhage [ICH] is the most feared complication of anticoagulant therapy [OAC]. Evidence regarding acute therapeutic interventions as well as secondary treatment approaches is still limited. Therefore, this German-wide observational cohort study will retrospectively identify and evaluate all OAC-associated ICH patients that have been admitted to the 20 participating tertiary centres over a 5-year period. The main focus of this investigation, besides epidemiological aspects, will be the (i) acute management of OAC-ICH, (ii) secondary therapy (anticoagulant management) and (iii) long-term outcome after OAC-ICH.

NCT ID: NCT01827046 Completed - Clinical trials for Intracerebral Hemorrhage

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

MISTIE-III
Start date: December 30, 2013
Phase: Phase 3
Study type: Interventional

A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).

NCT ID: NCT01805895 Completed - Clinical trials for Intracerebral Hemorrhage

A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients

MACH
Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral hemorrhage patients. The study will evaluation the safety and efficacy of minocycline in intracerebral hemorrhage patients.

NCT ID: NCT01702636 Completed - Stroke Clinical Trials

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

STOP-AUST
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

NCT ID: NCT01689402 Completed - Brain Neoplasms Clinical Trials

MRI for the Early Evaluation of Acute Intracerebral Hemorrhage

Start date: April 2012
Phase:
Study type: Observational

What happens in the borderzone of a cerebral hemorrhage remains widely onknown and furhter the best timing for doing MR to look for vascular pathology in cerebral hemorrhage has not yet been determined. In this study we do acute MRS, a non-invasive imaging mathod to detemine the biochemsty in the border zone and structural MRI for vascular malformation. We repeat structural MRI after 8 weeks.

NCT ID: NCT01619709 Completed - Clinical trials for Intracerebral Hemorrhage

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage

COGHIC-AV45
Start date: January 2012
Phase: N/A
Study type: Interventional

To evaluate Pet AV-45 Amyloid imaging in the etiological diagnosis of primary non traumatic intracerebral hemorrhage (Cerebral Amyloid Angiopathy and hypertension related hemorrhage).We hypothesize that patients with lobar hemorrhage (probably related to Cerebral Amyloid Angiopathy) will have a greater AV45 cortical binding than patients with deep hemorrhage (probably related to hypertension).

NCT ID: NCT01566786 Completed - Clinical trials for Acquired Bleeding Disorder

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Start date: August 2001
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) in preventing early haematoma growth in acute Intracerebral Haemorrhage (ICH).

NCT ID: NCT01563445 Completed - Clinical trials for Acquired Bleeding Disorder

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Start date: November 2001
Phase: Phase 2
Study type: Interventional

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) for preventing early hematoma growth in acute Intracerebral Hemorrhage (ICH).

NCT ID: NCT01472224 Completed - Stroke Clinical Trials

Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound

Start date: October 2011
Phase: N/A
Study type: Observational

This study investigates the ability of ultrasound to measure the volume of a brain hemorrhage in the acute phase after hospital admission. It is known that approximately 30% of patients admitted with a brain hemorrhage will suffer from enlargement of the hematoma within the first hours after admission. In this study the investigators measure the volume of the hematoma every 30 minutes up to 6 hours after admission and every 2 hours between 6-12 hours.

NCT ID: NCT01467206 Completed - Cerebral Infarction Clinical Trials

Life After STroke - the LAST Study

LAST
Start date: November 2011
Phase: N/A
Study type: Interventional

The LAST study is a Norwegian multi site randomised controlled trial that intends to assess the effect of a long term follow up program after stroke. The program consists of a coordinating physiotherapist who will encourage and motivate included patients to perform at least 60 minutes of intensive motor training every week and 30 minutes of physical activity every day for 18 months after inclusion. The primary hypothesis is that patients receiving a long term follow up program after stroke will have better motor function at end of follow up than patients receiving standard care. A total of 390 home dwelling stroke patients living in the municipality of Trondheim, Asker and Bærum will be included at the out-patient clinic at St. Olavs Hospital or Bærum Hospital three months after their stroke. Included patients will be randomised to an intervention group receiving the long term follow up program or to a control group receiving standard care. Motor function, mental health and physical functioning in daily life will be assessed at inclusion and 18 months later. The LAST study is funded by the Norwegian Research Council, the Norwegian University of Science and Technology and the Central Norway Regional Health Authority and will conclude at the end of 2015.